MX2014003288A - Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. - Google Patents

Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos.

Info

Publication number
MX2014003288A
MX2014003288A MX2014003288A MX2014003288A MX2014003288A MX 2014003288 A MX2014003288 A MX 2014003288A MX 2014003288 A MX2014003288 A MX 2014003288A MX 2014003288 A MX2014003288 A MX 2014003288A MX 2014003288 A MX2014003288 A MX 2014003288A
Authority
MX
Mexico
Prior art keywords
sulfur
compositions
preparation
highly bioavailable
rich compositions
Prior art date
Application number
MX2014003288A
Other languages
English (en)
Inventor
GOJON-ZORRILLA Gabriel
Gojon-Romanillos Gabriel
J Lefer David
Original Assignee
Nuevas Alternativas Naturales S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevas Alternativas Naturales S A P I De C V filed Critical Nuevas Alternativas Naturales S A P I De C V
Publication of MX2014003288A publication Critical patent/MX2014003288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención presenta composiciones ricas en azufre y preparaciones de las mismas que son seguras y efectivas como pro-fármacos de sulfuro de hidrogeno de alta bio-disponibilidad. La invención también incluye métodos para tratar condiciones patológicas asociadas con estrés oxidativo usando composiciones ricas en azufre. La invención además incluye composiciones ricas en azufre como antídotos y alimento médico para conservar y promover la salud mental.
MX2014003288A 2011-09-14 2012-09-13 Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. MX2014003288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534585P 2011-09-14 2011-09-14
PCT/US2012/055205 WO2013040240A1 (en) 2011-09-14 2012-09-13 Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof

Publications (1)

Publication Number Publication Date
MX2014003288A true MX2014003288A (es) 2017-03-09

Family

ID=47830038

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003289A MX360050B (es) 2011-09-14 2012-09-13 Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos.
MX2014003288A MX2014003288A (es) 2011-09-14 2012-09-13 Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014003289A MX360050B (es) 2011-09-14 2012-09-13 Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos.

Country Status (11)

Country Link
US (3) US20150064286A1 (es)
EP (2) EP2755478A4 (es)
JP (2) JP2014526511A (es)
CN (2) CN104080334A (es)
AU (3) AU2012308501A1 (es)
BR (3) BR112014005144B1 (es)
CA (2) CA2847589C (es)
ES (1) ES2739628T3 (es)
HK (2) HK1200277A1 (es)
MX (2) MX360050B (es)
WO (2) WO2013040240A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
WO2017011533A1 (en) 2015-07-13 2017-01-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Copolymerization of elemental sulfur to synthesize high sulfur content polymeric materials
US11015023B2 (en) 2011-08-11 2021-05-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Fire retardant compositions utilizing elemental sulfur
US11795248B2 (en) 2011-08-11 2023-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Copolymerization of elemental sulfur and epoxy functional styrenics
US9306218B2 (en) 2011-08-11 2016-04-05 Arizona Board Of Regents On Behalf Of The University Of Arizona High sulfur content copolymers and composite materials and electrochemical cells and optical elements using them
US9567439B1 (en) 2011-08-11 2017-02-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Sulfur composites and polymeric materials from elemental sulfur
US10920020B2 (en) 2011-08-11 2021-02-16 Arizona Board Of Regents On Behalf Of The University Of Arizona 3D-printing of ultra-high refractive index polymers
US20150064286A1 (en) * 2011-09-14 2015-03-05 Emory University Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
US10894863B2 (en) 2014-02-14 2021-01-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Cathode materials for Li—S batteries
KR20160122838A (ko) * 2014-02-14 2016-10-24 더 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 원소 황에서 유래된 황 복합체 및 폴리머 재료
US9795676B2 (en) 2014-03-03 2017-10-24 Shayne Kenneth Morris Chromium 4-hydroxyisoleucinate compound methods for prepartion and use
EP3151671A4 (en) * 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
JP6806965B2 (ja) * 2014-07-29 2021-01-06 国立大学法人 筑波大学 精子機能改善剤とこれを含む医薬品組成物、飼料、食品組成物及び家畜または家禽の精子機能改善方法
WO2016159612A1 (ko) * 2015-03-27 2016-10-06 서울대학교산학협력단 폴리설파이드 공중합체 나노입자 및 그의 제조 방법
US10238685B2 (en) * 2015-12-02 2019-03-26 Johnson & Johnson Consumer Inc. Compositions containing polymeric sulfur and uses thereof
US20170252369A1 (en) * 2016-03-03 2017-09-07 Frederick J. Sawaya Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases
CN107281215A (zh) * 2016-04-01 2017-10-24 复旦大学附属妇产科医院 硫化氢供体硫氢化钠在制药中的用途
US11649548B2 (en) 2016-12-09 2023-05-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Metallopolymers for catalytic generation of hydrogen
CN110461374B (zh) 2017-02-09 2022-05-31 诺克斯萨诺股份有限公司 电化学气体递质生成组合物及其使用方法和敷料以及包含其的治疗系统
US20180271823A1 (en) * 2017-03-23 2018-09-27 Washington State University Sulfur-based broad spectrum antivirals
US11674005B2 (en) 2017-06-15 2023-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Chalcogenide Hybrid Inorganic/organic Polymer (CHIP) materials as improved crosslinking agents for vulcanization
FR3072024A1 (fr) * 2017-10-11 2019-04-12 Olivier Petitjean Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale
CN108486081B (zh) * 2018-05-04 2021-07-02 山西大学 一种植物巯基丙酮酸硫转移酶及其应用
WO2020046635A1 (en) * 2018-08-28 2020-03-05 The Regents Of The University Of California Tetrathionate for cyanide and methylmercaptan poisoning
US20230165893A1 (en) * 2020-05-04 2023-06-01 Sulfagenix, Inc. Treatment of viral infections
FR3125409A1 (fr) * 2021-07-26 2023-01-27 Nuribiol Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine
IT202100021548A1 (it) * 2021-08-09 2023-02-09 Universita’ Di Pisa Coniugati della metformina e loro impiego terapeutico
WO2023079466A2 (en) * 2021-11-03 2023-05-11 Sulfagenix, Inc. Treatment of sequelae of coronavirus infections
EP4212149A1 (en) 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Oral dosage forms of acid-labile salt and methods and uses related thereto

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213050B (it) * 1986-03-14 1989-12-07 Schiena Ricerche Composizioni farmaceutiche topiche in odontostomatologia contenenti allantoina e zolfo elementare
US5100653A (en) * 1991-02-08 1992-03-31 Giovanni Campo Topical compositions for treating mouth tissues
US6514489B1 (en) 2000-06-30 2003-02-04 Medicis Pharmaceutical Corp. Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
US6855342B2 (en) * 2000-06-30 2005-02-15 Medicis Pharmaceutical Corporation Compositions and methods for high sorption of skin materials and delivery of sulfur
AUPS255402A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with oxidative stress
US20030235571A1 (en) 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US8361514B2 (en) * 2002-06-19 2013-01-29 Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
CN1320925C (zh) * 2005-03-30 2007-06-13 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂
US7741359B2 (en) 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
WO2007140588A1 (en) * 2006-06-02 2007-12-13 Natural Ma Inc. Pathogenic attenuation via the administration of an equilibiotic compound
US7923037B2 (en) 2006-10-05 2011-04-12 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
WO2008089439A2 (en) * 2007-01-18 2008-07-24 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
US20080318864A1 (en) * 2007-06-25 2008-12-25 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
WO2009004082A2 (en) 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
CN101467991B (zh) * 2007-08-02 2012-02-01 复旦大学 烯丙基半胱氨酸及其类似物在制备治疗心肌损伤药物中的用途
EP2326321A1 (en) 2008-09-12 2011-06-01 Inserm (Institut National de la Santé et de la Recherche Scientifique) Taurine or taurine-like substances for the prevention of brain oedema
RU2406477C1 (ru) 2009-08-25 2010-12-20 Федеральное государственное учреждение "Научно-исследовательский центр курортологии и реабилитации Федерального агентства по здравоохранению и социальному развитию" (ФГУ "НИЦКиР Росздрава") Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов
US8680151B2 (en) * 2010-02-11 2014-03-25 Fred Hutchinson Cancer Research Center Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury
US9096504B2 (en) * 2010-12-01 2015-08-04 Washington State University Controlled chemical release of hydrogen sulfide
US20150064286A1 (en) * 2011-09-14 2015-03-05 Emory University Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof

Also Published As

Publication number Publication date
BR112014005144B1 (pt) 2021-06-08
CN104080334A (zh) 2014-10-01
CA2847589A1 (en) 2013-04-18
CN104080339A (zh) 2014-10-01
WO2013055199A1 (es) 2013-04-18
AU2015210403A1 (en) 2015-09-03
MX2014003289A (es) 2016-05-16
US20140322361A1 (en) 2014-10-30
HK1200277A1 (en) 2015-08-07
CA2847264A1 (en) 2013-03-21
AU2012321444B2 (en) 2015-06-11
US8771755B2 (en) 2014-07-08
EP2755478A1 (en) 2014-07-23
ES2739628T3 (es) 2020-02-03
JP2014526511A (ja) 2014-10-06
EP2755478A4 (en) 2015-06-10
CA2847589C (en) 2019-11-26
AU2012308501A1 (en) 2014-03-13
BR122020020392B1 (pt) 2021-09-08
HK1200278A1 (en) 2015-08-07
US20130064904A1 (en) 2013-03-14
AU2012321444A1 (en) 2014-05-01
WO2013040240A1 (en) 2013-03-21
EP2756757A4 (en) 2015-05-20
AU2015210403B2 (en) 2016-11-24
EP2756757B1 (en) 2019-04-24
JP5992525B2 (ja) 2016-09-14
US20150064286A1 (en) 2015-03-05
AU2012321444A2 (en) 2014-05-15
EP2756757A1 (en) 2014-07-23
BR112014005144A2 (pt) 2017-04-18
BR112014004859A2 (pt) 2017-06-13
JP2014532042A (ja) 2014-12-04
AU2012308501A2 (en) 2014-04-17
MX360050B (es) 2018-10-19
CN104080339B (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
MX2014003288A (es) Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos.
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
EP2830637A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES RELATED TO OXIDATIVE STRESS
EA033374B9 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
EP2823043A4 (en) HIGHLY CONCENTRATED ALPHA-GLUCOSIDASE COMPOSITIONS FOR THE TREATMENT OF MORBUS POMPE
MY169328A (en) Compositions for the treatment of dry eye
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
ZA201408056B (en) Compositions and methods for the treatment of mucositis
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MX2015003701A (es) Composiciones para tratamiento.
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
WO2013120022A3 (en) Treatment of hypoglycemia
IL239374A0 (en) Preparations and methods for treating brain tumors
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
ZA201407010B (en) Process for the preparation of branched polybutadiene having high content of 1,4-cis units
KR101468123B9 (ko) 탯줄 유래 줄기세포를 포함하는 근위축 질환 개선 또는 치료용 조성물
EP2910247A4 (en) COMPOSITIONS FOR PREVENTING OR TREATING ALLERGIC SKIN DISORDERS CONTAINING GPCR19 AGENTS AS ACTIVE INGREDIENTS
MX2015006419A (es) Tratamiento de la intolerancia al gluten y padecimientos relacionados.
EA201491426A1 (ru) Новые фармацевтические композиции, содержащие фосфатидилсерин и куркумин
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
EP2935294A4 (en) METHOD AND COMPOSITIONS FOR TREATING CYANIDE AND SULFUR WATER STOT OXICITY
ZA201408065B (en) Compositions and methods for the treatment of diabetes